BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 24105104)

  • 1. Combined inhibition of PDE4 and PI3Kδ modulates the inflammatory component involved in the progression of chronic obstructive pulmonary disease.
    Dinavahi SS; Nyayapathy S; Perumal Y; Dharmarajan S; Viswanadha S
    Drug Res (Stuttg); 2014 Apr; 64(4):214-9. PubMed ID: 24105104
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Roflumilast N-oxide reverses corticosteroid resistance in neutrophils from patients with chronic obstructive pulmonary disease.
    Milara J; Lluch J; Almudever P; Freire J; Xiaozhong Q; Cortijo J
    J Allergy Clin Immunol; 2014 Aug; 134(2):314-22. PubMed ID: 24636089
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The preclinical pharmacology of roflumilast--a selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease.
    Hatzelmann A; Morcillo EJ; Lungarella G; Adnot S; Sanjar S; Beume R; Schudt C; Tenor H
    Pulm Pharmacol Ther; 2010 Aug; 23(4):235-56. PubMed ID: 20381629
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Roflumilast N-oxide inhibits bronchial epithelial to mesenchymal transition induced by cigarette smoke in smokers with COPD.
    Milara J; Peiró T; Serrano A; Guijarro R; Zaragozá C; Tenor H; Cortijo J
    Pulm Pharmacol Ther; 2014 Aug; 28(2):138-48. PubMed ID: 24525294
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Pharmacological profile of roflumilast].
    Cortijo Gimeno J; Morcillo Sánchez E
    Arch Bronconeumol; 2010 Dec; 46 Suppl 10():19-24. PubMed ID: 21316552
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Roflumilast N-oxide prevents cytokine secretion induced by cigarette smoke combined with LPS through JAK/STAT and ERK1/2 inhibition in airway epithelial cells.
    Victoni T; Gleonnec F; Lanzetti M; Tenor H; Valença S; Porto LC; Lagente V; Boichot E
    PLoS One; 2014; 9(1):e85243. PubMed ID: 24416369
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Simvastatin Increases the Ability of Roflumilast N-oxide to Inhibit Cigarette Smoke-Induced Epithelial to Mesenchymal Transition in Well-differentiated Human Bronchial Epithelial Cells in vitro.
    Milara J; Peiró T; Serrano A; Artigues E; Aparicio J; Tenor H; Sanz C; Cortijo J
    COPD; 2015 Jun; 12(3):320-31. PubMed ID: 25207459
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The modulatory effects of the PDE4 inhibitors CHF6001 and roflumilast in alveolar macrophages and lung tissue from COPD patients.
    Lea S; Metryka A; Li J; Higham A; Bridgewood C; Villetti G; Civelli M; Facchinetti F; Singh D
    Cytokine; 2019 Nov; 123():154739. PubMed ID: 31319374
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Roflumilast inhibits leukocyte-platelet interactions and prevents the prothrombotic functions of polymorphonuclear leukocytes and monocytes.
    Totani L; Amore C; Di Santo A; Dell'Elba G; Piccoli A; Martelli N; Tenor H; Beume R; Evangelista V
    J Thromb Haemost; 2016 Jan; 14(1):191-204. PubMed ID: 26484898
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-neutrophilic inflammatory activity of ASP3258, a novel phosphodiesterase type 4 inhibitor.
    Kubo S; Kobayashi M; Iwata M; Miyata K; Takahashi K; Shimizu Y
    Int Immunopharmacol; 2012 Jan; 12(1):59-63. PubMed ID: 22041526
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic evaluation of roflumilast.
    Lahu G; Nassr N; Hünnemeyer A
    Expert Opin Drug Metab Toxicol; 2011 Dec; 7(12):1577-91. PubMed ID: 22059647
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phosphodiesterase 4 inhibitors augment the ability of formoterol to enhance glucocorticoid-dependent gene transcription in human airway epithelial cells: a novel mechanism for the clinical efficacy of roflumilast in severe chronic obstructive pulmonary disease.
    Moodley T; Wilson SM; Joshi T; Rider CF; Sharma P; Yan D; Newton R; Giembycz MA
    Mol Pharmacol; 2013 Apr; 83(4):894-906. PubMed ID: 23389862
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phosphodiesterase-4 inhibition augments human lung fibroblast vascular endothelial growth factor production induced by prostaglandin E2.
    Ikari J; Michalski JM; Iwasawa S; Gunji Y; Nogel S; Park JH; Nelson AJ; Farid M; Wang X; Schulte N; Basma H; Toews ML; Feghali-Bostwick C; Tenor H; Liu X; Rennard SI
    Am J Respir Cell Mol Biol; 2013 Oct; 49(4):571-81. PubMed ID: 23656623
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Roflumilast: doubtful efficacy but clear harms in COPD.
    Prescrire Int; 2013 Jan; 22(134):5-9. PubMed ID: 23367674
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Additive anti-inflammatory effects of beta 2 adrenoceptor agonists or glucocorticosteroid with roflumilast in human peripheral blood mononuclear cells.
    Tannheimer SL; Sorensen EA; Haran AC; Mansfield CN; Wright CD; Salmon M
    Pulm Pharmacol Ther; 2012 Apr; 25(2):178-84. PubMed ID: 22306235
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The unrecognized effects of phosphodiesterase 4 on epithelial cells in pulmonary inflammation.
    Konrad FM; Bury A; Schick MA; Ngamsri KC; Reutershan J
    PLoS One; 2015; 10(4):e0121725. PubMed ID: 25909327
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting phosphoinositide-3-kinase-delta with theophylline reverses corticosteroid insensitivity in chronic obstructive pulmonary disease.
    To Y; Ito K; Kizawa Y; Failla M; Ito M; Kusama T; Elliott WM; Hogg JC; Adcock IM; Barnes PJ
    Am J Respir Crit Care Med; 2010 Oct; 182(7):897-904. PubMed ID: 20224070
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hybrids consisting of the pharmacophores of salmeterol and roflumilast or phthalazinone: dual β₂-adrenoceptor agonists-PDE4 inhibitors for the treatment of COPD.
    Liu A; Huang L; Wang Z; Luo Z; Mao F; Shan W; Xie J; Lai K; Li X
    Bioorg Med Chem Lett; 2013 Mar; 23(5):1548-52. PubMed ID: 23375225
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Direct Inhibitory Effect of the PDE4 Inhibitor Roflumilast on Neutrophil Migration in Chronic Obstructive Pulmonary Disease.
    Dunne AE; Kawamatawong T; Fenwick PS; Davies CM; Tullett H; Barnes PJ; Donnelly LE
    Am J Respir Cell Mol Biol; 2019 Apr; 60(4):445-453. PubMed ID: 30395484
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Novel trends in pharmacotherapy of chronic obstructive pulmonary disease--prevention of exacerbations (focus on roflumilast)].
    Sinopal'nikov AI
    Klin Med (Mosk); 2014; 92(2):57-64. PubMed ID: 25269184
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.